These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29976634)

  • 41. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
    Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
    Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin.
    Asayama Y; Taguchi Ki K; Aishima Si S; Nishi H; Masuda K; Tsuneyoshi M
    Liver; 2002 Feb; 22(1):43-50. PubMed ID: 11906618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis.
    Kim TH; Kim H; Joo I; Lee JM
    Korean J Radiol; 2020 Oct; 21(10):1115-1125. PubMed ID: 32729276
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition.
    Seok JY; Na DC; Woo HG; Roncalli M; Kwon SM; Yoo JE; Ahn EY; Kim GI; Choi JS; Kim YB; Park YN
    Hepatology; 2012 Jun; 55(6):1776-86. PubMed ID: 22234953
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.
    Sapisochin G; de Lope CR; Gastaca M; de Urbina JO; López-Andujar R; Palacios F; Ramos E; Fabregat J; Castroagudín JF; Varo E; Pons JA; Parrilla P; González-Diéguez ML; Rodriguez M; Otero A; Vazquez MA; Zozaya G; Herrero JI; Antolin GS; Perez B; Ciria R; Rufian S; Fundora Y; Ferron JA; Guiberteau A; Blanco G; Varona MA; Barrera MA; Suarez MA; Santoyo J; Bruix J; Charco R
    Ann Surg; 2014 May; 259(5):944-52. PubMed ID: 24441817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas.
    Cazals-Hatem D; Rebouissou S; Bioulac-Sage P; Bluteau O; Blanché H; Franco D; Monges G; Belghiti J; Sa Cunha A; Laurent-Puig P; Degott C; Zucman-Rossi J
    J Hepatol; 2004 Aug; 41(2):292-8. PubMed ID: 15288479
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series.
    De Vito C; Sarker D; Ross P; Heaton N; Quaglia A
    Virchows Arch; 2017 Nov; 471(5):619-629. PubMed ID: 28707055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cancer related gene alterations can be detected with next-generation sequencing analysis of bile in diffusely infiltrating type cholangiocarcinoma.
    Lee CH; Wang HE; Seo SY; Kim SH; Kim IH; Kim SW; Lee ST; Kim DG; Han MK; Lee SO
    Exp Mol Pathol; 2016 Aug; 101(1):150-6. PubMed ID: 27460275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma.
    Groeschl RT; Turaga KK; Gamblin TC
    J Surg Oncol; 2013 May; 107(6):608-12. PubMed ID: 23386397
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma.
    Ishii T; Ito T; Sumiyoshi S; Ogiso S; Fukumitsu K; Seo S; Taura K; Uemoto S
    World J Surg Oncol; 2020 Dec; 18(1):319. PubMed ID: 33276780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
    Gurzu S; Szodorai R; Jung I; Banias L
    J Cancer Res Clin Oncol; 2024 May; 150(5):270. PubMed ID: 38780656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
    Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
    Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined hepatocellular-cholangiocarcinomas exhibit progenitor features and activation of Wnt and TGFβ signaling pathways.
    Coulouarn C; Cavard C; Rubbia-Brandt L; Audebourg A; Dumont F; Jacques S; Just PA; Clément B; Gilgenkrantz H; Perret C; Terris B
    Carcinogenesis; 2012 Sep; 33(9):1791-6. PubMed ID: 22696594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
    Calderaro J; Ghaffari Laleh N; Zeng Q; Maille P; Favre L; Pujals A; Klein C; Bazille C; Heij LR; Uguen A; Luedde T; Di Tommaso L; Beaufrère A; Chatain A; Gastineau D; Nguyen CT; Nguyen-Canh H; Thi KN; Gnemmi V; Graham RP; Charlotte F; Wendum D; Vij M; Allende DS; Aucejo F; Diaz A; Rivière B; Herrero A; Evert K; Calvisi DF; Augustin J; Leow WQ; Leung HHW; Boleslawski E; Rela M; François A; Cha AW; Forner A; Reig M; Allaire M; Scatton O; Chatelain D; Boulagnon-Rombi C; Sturm N; Menahem B; Frouin E; Tougeron D; Tournigand C; Kempf E; Kim H; Ningarhari M; Michalak-Provost S; Gopal P; Brustia R; Vibert E; Schulze K; Rüther DF; Weidemann SA; Rhaiem R; Pawlotsky JM; Zhang X; Luciani A; Mulé S; Laurent A; Amaddeo G; Regnault H; De Martin E; Sempoux C; Navale P; Westerhoff M; Lo RC; Bednarsch J; Gouw A; Guettier C; Lequoy M; Harada K; Sripongpun P; Wetwittayaklang P; Loménie N; Tantipisit J; Kaewdech A; Shen J; Paradis V; Caruso S; Kather JN
    Nat Commun; 2023 Dec; 14(1):8290. PubMed ID: 38092727
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined hepatocellular cholangiocarcinoma in hepatectomy specimens: A clinicopathologic analysis.
    Patil N; Sahai P; Rastogi A; Sharma N; Shasthry SM; Mukund A; Laroia ST; Kumar G; Pamecha V; Sarin SK
    Indian J Pathol Microbiol; 2023; 66(4):744-750. PubMed ID: 38084526
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined hepatocellular carcinoma and cholangiocarcinoma: a case report and review of the literature.
    Zhou YM; Yang JM; Wang B; Xu F; Tong Y; Li DQ
    Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):656-9. PubMed ID: 18086637
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.
    Zhao Q; Yu WL; Lu XY; Dong H; Gu YJ; Sheng X; Cong WM; Wu MC
    Chin J Cancer; 2016 Aug; 35(1):82. PubMed ID: 27552844
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Review on the Update of Combined Hepatocellular Cholangiocarcinoma.
    Komuta M; Yeh MM
    Semin Liver Dis; 2020 May; 40(2):124-130. PubMed ID: 31887773
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.
    Ono Y; Hiratsuka Y; Murata M; Takasawa A; Fukuda R; Nojima M; Tanaka S; Osanai M; Hirata K; Sawada N
    Virchows Arch; 2016 Oct; 469(4):417-26. PubMed ID: 27444172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.